1.Relationship of loneliness and subjective chewing discomfort in the elderly
Hye-Kyong CHO ; Yun-Sook JUNG ; Hyo-Jin HEO ; Yoo-Sik YOUM ; Keun-Bae SONG ; Youn-Hee CHOI
Journal of Korean Academy of Oral Health 2020;44(2):85-90
Objectives:
Loneliness was associated with not only social status but also general health. Psychological conditions in older people have negative effects on general health and oral health. The purpose of the study was to investigate the relationship between loneliness and subjective chewing discomfort in the elderly.
Methods:
This cross-sectional study analyzed the Korean Social Life, Health, and Aging Project (KSHAP) for the questionnaire, UCLA loneliness scale data of 1,511 older adults living in a rural community. Logistic regression was conducted to identify the relevance of subjective chewing discomfort in the elderly according to the level of loneliness.
Results:
According to the final model that after adjustment for other risk factors (age, gender, level of education, smoking, drinking, etc.), in the elderly who rarely feel loneliness group compared to the elderly who never feel loneliness was Odds ratio (OR) 1.256 (95% Confidence Interval [CI]: 0.99-1.60) and sometimes+often feel loneliness was OR 2.110 (95% CI: 1.39-3.21).
Conclusions
Loneliness is associated with subjective chewing discomfort in the elderly. Older people feeling loneliness are likely to have more subjective chewing discomfort.
2.Development of the Korean Academy of Medical Sciences Guideline for Rating Physical Impairment.
Kyeong Seok LEE ; Jong Uk WON ; So Yun KIM ; Myong Sei SOHN ; Yoo Sik YOUM ; Yoon Seong LEE ; Dong Jun KIM ; Soo Hun CHO ; Mi Jin LEE ; Jong Sang CHOI
Journal of Korean Medical Science 2009;24(Suppl 2):S221-S226
Systematic and effective welfare for the disabled is possible when there are scientific and objective criteria demonstrating either presence or severity of the impairment. We need our own scientific criteria suitable for our culture and society, since the impairment is influenced by them. In 2007, we established the Developing Committee of Korean Academy of Medical Sciences (KAMS) Guideline for Impairment Rating under KAMS supervision. We included all fixed and permanent physical impairments after a sufficient medical treatment. The impairment should be stable and medically measurable. If not, it should be reevaluated later. We benchmarked the American Medical Association Guides. The KAMS Guideline should be scientific, objective, valid, reasonable and practical. In particular, we tried to secure objectivity. We developed the KAMS Guideline for Impairment Rating.
*Disability Evaluation
;
Humans
;
Korea
;
Program Development
;
Questionnaires
;
*Severity of Illness Index
3.Rituximab Treatment for the Patient with Refractory Lupus Nephritis.
Ji Youn YOUM ; Yoon Kyoung SUNG ; Wan Sik UHM ; Jae Bum JUN ; Dae Hyun YOO ; Sang Cheol BAE
The Journal of the Korean Rheumatism Association 2005;12(4):251-262
OBJECTIVE: To determine preliminary evidence for the safety and efficacy of B lymphocyte depletion therapy in refractory systemic lupus erythematosus (SLE). METHODS: Four female lupus nephritis patients who had been refractory to steroid and one or more immunosuppressive therapy were treated on an open-label basis. During a 4-week period, each patient received two 500-mg infusions of rituximab and two 750-mg infusions of cyclophosphamide. RESULTS: Patient 1, 2, and 3 were responded with rituximab treatment with improvements in SLEDAI and laboratory parameters such as C3/C4 and 24 hour urine protein. However, patient 4 had not improved with rituximab. The variation in the level of anti-double-stranded DNA antibody was different in individual patients. No significant adverse events were observed during follow-up. CONCLUSION: This study provides an evidence for the safety and possible efficacy of B lymphocyte depletion therapy in refractory lupus nephritis. However a further randomized trial is needed to confirm the efficacy and durability of remission.
Cyclophosphamide
;
DNA
;
Female
;
Follow-Up Studies
;
Humans
;
Lupus Erythematosus, Systemic
;
Lupus Nephritis*
;
Lymphocyte Depletion
;
Rituximab